More than once, I've made the point that one of the hardest parts of
biotech investing is the interminable waiting periods between clinical
data. In the absence of anything real to go on, stocks can get batted
around by data from rivals, bullish or bearish sell-side reports, and
bullish/bearish commentaries from writers like myself. While there is
nothing new in hand to help determine if Rigel Pharmaceuticals' (RIGL)
lead drug R788 will prove to be safe, effective, approvable, and
commercially viable in the oral rheumatoid arthritis (RA) market, we are
about six months closer to knowing and this stock remains an appealing
speculation.
Continue reading here:
The Waiting May Be The Hard Part For Rigel Pharmaceuticals
No comments:
Post a Comment